September 14, 2018 6:20pm
As the markets dived along with the IBB (-0.51%)
Don't not ignore the week’s choppiness
Pre-open indications: 3 HIT and 0 MISS
Who is defining the metrics for individual investors and which broker, trader, fund or I-Bank is keeping you notified of the sector and market fluctuations?
I put the facts into evidence!
RMi’s daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined and evaluated.
Henry’omics:
The storm news has dominated the news; as investors keep an eye on Hurricane Florence which touched down in the Carolinas on Friday pounding the southern coastline with heavy rains and wind.
- Today’s major indexes gave back their slight gains but stabilized at the close.
For the week, the Dow rose 0.9%; the S&P 500 gained 1.2%, flirting with a record close, while the NASDAQ booked a 1.4% weekly gain.
From the pre-open newsletter: “the final trading day of the week, TGIF. Is the upside on borrowed time; or, are we ready for “ascension”; I’m a sinner and a saint when it comes to a value proposition … the problem is many have little faith in these markets.”
The sector closed (luckily) up after a depreciated open.
Next week’s trading sessions will be critical for the RegMed sector which will establish whether market reaction to recent events is temporary and short-lived, or if this is the start of a more fundamental correction.
- One wildcard could be an announcement of clinical data but I don’t anticipate … ANY!
Pricing has been percolating on the low end (percentage) of trading ranges. Most of the RegMed equities are … well below I-Bank price target … and they (analysts) still haven’t re-adjusted and they won’t.
I still maintain, “The key is trading the ups, buying the lows so they can eventually be the overbought through unbridled speculation and then trade again.”
Remember, the count-down to the end of the month and Q3 is rapidly approaching – we are half-way there!
This week’s spits and spurts:
AGTC closed flat after having slipped negative on Thursday -$0.05 to $3.90 after Wednesday’s +$0.03 after getting nailed post Q4 and FY18 reporting (-$0.375);
BLFS recaptured altitude (+$0.37) having declined Thursday -$0.93 to $18.15 after Wednesday’s -$0.50 following Tuesday’s -$0.44, as I had stated - another Icarus flight pattern waiting for a melting dive;
BSTG closed down -$0.20 to $2.80 after Thursday’s $3.00, Wednesday’s $3.10, Tuesday’s $3.40 and Monday’s close of $3.40 – there is a history of miss-steps in this company and non-fulfillment of promised results and the same individuals are running this “s - -t” show (my opinion of reverse spit criminals);
CLBS was down -$0.04 to $5.53 having started the week at $5.48 and gone barely anywhere having called the company an” over-dated egg salad sandwich and a ptomaine portfolio holding” – watch for the next quarters loss-per-share based on oversized spending;
VSTM jumped Friday +$0.14 after Thursday’s drop of -$0.06 after Wednesday’s -$0.31 following Tuesday appreciation of +$0.12 with increasing volume – October is getting closer;
HSGX was down again -$0.05 following Thursday’s -$0.059 after Wednesday’s -$0.0167 after being barely up, the shell and cash is worth more than today’s $0.53;
BLUE bounced down again -$2.35 to $146.10 from Thursday’s +$0.90 after Wednesday’s -$5.45 following Tuesday’s -$5.00 – back and forth as the month slows to an end;
RGNX bounced back another +$7.60 to $81.20 after Thursday’s +$0.85, Wednesday’s slip of -$1.55 and Tuesday’s gain of +$1.90, regaining altitude and attitude;
The CRISPR trio– they are getting “RIPE” to be profited while retracing lost value until the next decline (I wouldn’t hold my breath:
- CRSP closed up again (Friday) +$1.21 to $55.36 after Thursday’s +$0.42, Wednesday’s +$1.93 after Tuesday’s +$2.11 … following Monday’s close of $49.69;
- EDIT closed up +$0.19 to $32.41 on Friday after being down -0.27 post Wednesday’s +$0.25 after Tuesday’s +$1.17 … following Monday’s close of $31.07;
- NTLA closed up +$0.08 to $31.05 on Friday after Thursday’s +$0.70, Wednesday’s +$1.14 and Tuesday’s +$2.015 … following Monday’s close of $26.98;
Of the 45 companies covered on Friday; 19 downside equities finished in a range of -0.05% (VYGR) to -9.23% (HSGX) while 23 upside equity oscillated from +0.03% (SAGE) to +10.33% (RGNX) with 3 flat closes (AST, AGTC and ADVM).
Daily analytics and metrics:
- The Dow closed barely up +8.68 or +0.03% to 26,154.67
- The S&P closed up +0.80 or +0.03% to 2,904.98
- The NASDAQ closed down -3.67 or -0.05% to 8,010.04
The advance/decline line scenario of 45 covered companies:
- The open was negative with an A/DL of 16/26 and 3 flats;
- The first hour saw a positive A/DL of 31/13 and 1 flat;
- The mid-day was positive with an A/DL of 24/17 and 4 flats;
- The close was positive with an A/DL of 23/19 and 3 flats;
Pre-open indications: 3 TRADES – volume is running high versus last week
- CRISPR Therapeutics (CRSP) closed up $1.21 to $55.36 - hit;
- Editas Medicine (EDIT) closed up +$0.19 to $32.41– hit;
- Intellia Therapeutics (NTLA) closed up +$0.08 to $31.05 – hit;
Five (5) key metrics:
… The greatest volume to the downside: BMRN, HSGX, AXGN, XON and ATHX
… Upside volume was weighted to: VSTM, MDXG, SGMO, RGNX and IONS
… Leadership ($) to the downside: BLUE (-$2.35), RENE.L (-$1.50), AXGN (-$1.10), GBT (-$0.50) and XON (-$0.25)
… Best moves ($) to the upside: RGNX (+$7.60), ALNY (+$2.18), RARE (+$2.110, BOLD (+$1.47) and SLDB (+$1.47)
The iShares NASDAQ Biotechnology (IBB) closed:
- Friday was down 0.51%
- Thursday was up +0.74%
- Wednesday was up +0.05%
- Tuesday was down -0.42%
- Monday was up +0.17%
- Last Friday was down -0.57%
September sessions:
Friday’s closed POSITIVE with 19 decliners, 23 advancer and 3 flats
Thursday’s closed NEGATIVE with 22 decliners, 20 advancer and 3 flats
Wednesday’s closed POSITIVE with 20 decliners, 25 advancer and 0 flats
Tuesday’s closed POSITIVE with 20 decliners, 23 advancer and 2 flats
Monday’s closed NEGATIVE with 28 decliners, 17 advancer and 2 flats
Friday’s closed POSITIVE with 15 decliners, 23 advancer and 7 flats
Thursday’s closed NEGATIVE with 39 decliners, 1 advancer and 5 flats
Wednesday’s closed NEGATIVE with 30 decliners, 12 advancers and 3 flats
Tuesday’s (9/4) closed NEGATIVE with 22 decliners, 19 advancers and 4 flats
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
